reviewThe LancetDec 7, 2016Closed access

HER2-positive breast cancer

German Breast group · San Raffaele University of Rome

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,102
total citations
FWCI
22.80
Percentile
100%
References
97
Citations per year

Authors

2

Topics & keywords

Keywords
  • Pertuzumab
  • Trastuzumab
  • Medicine
  • Breast cancer
  • Oncology
  • Internal medicine
  • Adjuvant
  • Clinical trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.